Buscar
Abcellera Biologics Inc
ABCLAñadir a la lista de seguimiento
7.600USD
-0.250-3.18%
Cierre 07/01, 16:00（ET）Cotizaciones retrasadas 15 min
2.32BCap. mercado
PérdidaP/E TTM
Más Datos de Abcellera Biologics Inc Compañía
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Información de Abcellera Biologics Inc
Símbolo de cotizaciónABCL
Nombre de la empresaAbcellera Biologics Inc
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoHansen (Carl L.G)
Número de empleados596
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 11
Dirección150 W 4Th Avenue
CiudadVANCOUVER
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalV5Y 1G6
Teléfono16045599005
Sitio Webhttps://www.abcellera.com/
Símbolo de cotizaciónABCL
Fecha de salida a bolsaDec 11, 2020
Director ejecutivoHansen (Carl L.G)
Ejecutivos de Abcellera Biologics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
576.56K
+43.36%
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Abcellera Biologics Inc?
Los cinco principales accionistas de Abcellera Biologics Inc son: Dr. Veronique Lecault, Ph.D.
¿Cuántas instituciones poseen acciones de Abcellera Biologics Inc (ABCL)?
A fecha de 2026Q1, 323 instituciones poseen acciones de Abcellera Biologics Inc, con un valor de mercado combinado de aproximadamente 131.69M, lo que representa el 43.14% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -19217264.00.
¿Cuál es la mayor fuente de ganancias de Abcellera Biologics Inc?
El 2026Q1, el segmento empresarial Licensing revenue generó la ganancia más alta para Abcellera Biologics Inc, ascendiendo a 46.92M y representando el 62.45% de la ganancia total.